Identification of the antibodies involved in B-cell crossmatch positivity in renal transplantation
Authors:
- Stéphanie Le Bas-BernardetSBStéphanie Le Bas-Bernardet
- Maryvonne HourmantMHMaryvonne Hourmant
- Nathalie ValentinNVNathalie Valentin
- Catherine PaitierCPCatherine Paitier
- Magali Giral-ClasseMGMagali Giral-Classe
- Sylvie CurrySCSylvie Curry
- Gilles FolleaGFGilles Follea
- Jean-Paul SoulillouJSJean-Paul Soulillou
- Jean-Denis BignonJBJean-Denis Bignon
- 27 February 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 75 (4) , 477-482
Abstract
The significance of a positive B-cell crossmatch (BCM) in kidney transplantation has always been controversial in the evaluation of its implications on graft survival and specificity of the antibodies involved. We have investigated the sera of 62 recipients of a kidney allograft transplanted across a positive BCM (T negative) for the presence of autoantibodies and anti-human leukocyte antigen (HLA) class I and II antibodies, using a combination of lymphocytotoxicity, enzyme-linked immunosorbent assay (ELISA), and flow cytometry tests. The controls were the 930 patients transplanted over the same period of time with a negative T and BCM. Autoantibodies were detected in 16%, and donor specific anti-HLA class II antibodies, mainly DQ, in 23% of the patients. None had antibodies against donor HLA class I. The target of the antibodies was not identified in 61%. Graft survival was comparable in the controls and in the +BCM patients, with nondonor-specific HLA reactivity. Patients with donor-specific anti-HLA class II antibodies had lower early graft survival and a higher incidence of vascular rejection. However, long-term allograft survival was similar to that of the other groups. These data suggest that in 77% of the patients, BCM positivity was not related with anti-HLA antibodies, and, in this case, graft survival was similar to that of the −BCM controls. In a minority of patients, anti-HLA class II antibodies were responsible for the +BCM, and their presence was associated with lower early, but not long-term, graft survival. Consequently, a +BCM should not systematically contraindicate kidney transplantation.Keywords
This publication has 21 references indexed in Scilit:
- SPECIFICITY AND Ig CLASS OF PREFORMED ALLOANTIBODIES CAUSING A POSITIVE CROSSMATCH IN RENAL TRANSPLANTATIONTransplantation, 1993
- HYPERACUTE AND ACUTE KIDNEY GRAFT REJECTION DUE TO ANTIBODIES AGAINST B CELLSTransplantation, 1992
- Randomized Controlled Trial of a Monoclonal Antibody against the Interleukin-2 Receptor (33B3.1) as Compared with Rabbit Antithymocyte Globulin for Prophylaxis against Rejection of Renal AllograftsNew England Journal of Medicine, 1990
- CHARACTERIZATION AND SIGNIFICANCE OF DONOR-REACTIVE B CELL ANTIBODIES IN CURRENT SERA OF KIDNEY TRANSPLANT PATIENTSTransplantation, 1990
- Renal Allograft Survival in Patients with Positive B Cell Crossmatch to Their DonorAnnals of Surgery, 1984
- CADAVER RENAL TRANSPLANT OUTCOME IN RECIPIENTS WITH AUTOLYMPHOCYTOTOXIC ANTIBODIESTransplantation, 1983
- Successful transplantation with a positive T and B cell crossmatch due to autoreactive antibodiesTissue Antigens, 1983
- HYPERACUTE REJECTION OF HLA-AB-IDENTICAL RENAL ALLOGRAFTS ASSOCIATED WITH B LYMPHOCYTE AND ENDOTHELIAL REACTIVE ANTIBODIESTransplantation, 1982
- DONOR-SPECIFIC B AND T LYMPHOCYTE ANTIBODIES AND KIDNEY GRAFT SURVIVALTransplantation, 1981
- SUCCESSFUL RENAL ALLOGRAFTS ACROSS A POSITIVE CROSS-MATCH FOR DONOR B-LYMPHOCYTE ALLOANTIGENSThe Lancet, 1976